Effect of empagliflozin/linagliptin on oxidative stress markers in chronic kidney patient with type 2 diabetes stage 3: A randomized, open label controlled trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20210322002

Enrollment

Registered

2021-03-22

Start date

2020-07-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Reactive oxidative stress in T2DM with CKD stage III with HbA1c 7-10% Reactive oxidative stress in T2DM with CKD stage III with HbA1c 7-10%

Interventions

other standard treatment ,empagliflozin 5 mg and linagliptin 10 mg 1 tab OD

Active Comparator Drug,Experimental Drug

Control group,SGLT2i and DPP4i

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: eGFR 30-59 ml/min/1.73m2 T2DM HbA1c 7-10% No treatment adjusted with anti-HT within 1 months

Exclusion criteria

Exclusion criteria: T1DM or secondary diabetes History of diabetic ketoacidosis Current history of urinary and genital tract infection Pancreatic and active liver disease proliferative diabetic retinopathy Recent smoking < 6 month Herbal medicine use Active infection Active malignancy Alzheimer disease Pregnancy Breast feeding

Design outcomes

Primary

Measure	Time frame
urine 8OHdg baseline and 12 week ELISA	—

Secondary

Measure	Time frame
UACR baseline and 12 weeks urine	—

Countries

Thailand

Contacts

Public ContactSupaporn Suebsiripong

Department of internal Medicine, Phramongkutklao Hospital

byebye_bumpfakt@hotmail.com0824686858

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026